These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 32353614

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kovácsházi C, Giricz Z, Brenner GB, Ferdinandy P, Schaart G, Gemmink A, Hesselink MKC, Rivaud MR, Pieper MP, Hollmann MW, Weber NC, Balligand JL, Creemers EE, Coronel R, Zuurbier CJ.
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [Abstract] [Full Text] [Related]

  • 44. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes.
    Pabel S, Reetz F, Dybkova N, Shomroni O, Salinas G, Mustroph J, Hammer KP, Hasenfuss G, Hamdani N, Maier LS, Streckfuss-Bömeke K, Sossalla S.
    J Mol Med (Berl); 2020 Dec; 98(12):1689-1700. PubMed ID: 33034709
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M, Klöting N, Mark M, Mayoux E, Klein T, Blüher M.
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice.
    Croteau D, Luptak I, Chambers JM, Hobai I, Panagia M, Pimentel DR, Siwik DA, Qin F, Colucci WS.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e019995. PubMed ID: 34169737
    [Abstract] [Full Text] [Related]

  • 55. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, Nakata K, Kimura Y, Tanno M, Miura T.
    Physiol Rep; 2018 Jun 06; 6(12):e13741. PubMed ID: 29932506
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
    Bugga P, Mohammed SA, Alam MJ, Katare P, Meghwani H, Maulik SK, Arava S, Banerjee SK.
    Life Sci; 2022 Oct 15; 307():120862. PubMed ID: 35934058
    [Abstract] [Full Text] [Related]

  • 58. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL.
    Cardiovasc Diabetol; 2018 Apr 27; 17(1):62. PubMed ID: 29703207
    [Abstract] [Full Text] [Related]

  • 59. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V.
    Am J Physiol Renal Physiol; 2018 Aug 01; 315(2):F386-F394. PubMed ID: 29412698
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.